BRIEF-FDA Approves Treosulfan With Fludarabine As A Preparative Regimen For Allohsct In Adult And Pediatric Patients With Aml Or Mds
ReutersFeb 6, 2025 8:53 PM
Feb 6 (Reuters) - FDA :
FDA APPROVES TREOSULFAN WITH FLUDARABINE AS A PREPARATIVE REGIMEN FOR ALLOHSCT IN ADULT AND PEDIATRIC PATIENTS WITH AML OR MDS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
U.S. Stock Market Risk Assessment: Learning from History, Mid-Term Outlook Remains Secure
We argue that the Federal Reserve’s monetary policy is the most critical factor influencing the stock market.TradingKey
Mon, Aug 18
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed ChairTradingKey
Mon, Aug 18
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
What to Expect From Meta Q2 Earnings: AI Push, Ad Strength — But Can Profitability Hold?
TradingKey - Meta Platforms (META), the parent company of Facebook, Instagram, and WhatsApp, will release its Q2 2025 earnings after the U.S. market close on Wednesday, July 30. After nine consecutive quarters of beating expectations, analysts expect another strong performance — driven by AI-poweredTradingKey
Tue, Jul 29
Cathie Wood’s ARK: The Ever-Volatile Bet on Innovation
Cathie Wood's ARK Investment Management is basically synonymous with high-conviction, high-volatility bets on disruptive innovation. It is not a run-of-the-mill mutual fund with safe bets in consumer staples or diversified blue chips, a deliberate swing at future-shaping businessesTradingKey
Fri, Jul 25
